The World Health Organization (WHO) on Monday recommended countries to use the twice-a-year lenacapavir injection as an add ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Yeztugo (generic name lenacapavir), which is given by health care workers in clinics, is significantly more effective than the existing oral HIV-prevention drugs, experts said, because it appears ...

FOSTER CITY, Calif., June 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s ...

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...

Yeztugo (lenacapavir) is the first and only injectable drug that can prevent HIV acquired through sexual contact with just two injections a year. Clinical trials showed that the medication ...

Gilead and its partners' efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...